Massive study checks if ozempic protects hearts and kidneys better than other diabetes meds
NCT ID NCT07456774
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This large study looks back at medical records of 100,000 Chinese patients with type 2 diabetes to compare heart and kidney outcomes between those taking Ozempic and those on other diabetes drugs. Researchers will track major heart problems, strokes, and kidney events. The goal is to see if Ozempic offers extra protection beyond blood sugar control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
semaglutide (Ozempic)
What this could lead to
If results show Ozempic is better for heart and kidney health, it could guide doctors in choosing diabetes treatments.
What could go wrong
This is a retrospective study, so it can't prove cause and effect. Results may be influenced by other factors and may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NIS- Tianjin Medical University Chu Hsien-I Memorial Hospital-Department of Endocrinology
Tianjin, Tianjin Municipality, 300074, China